The company is focused on advancing its NNMT inhibitors through further research and development, with the goal of offering new therapies for metabolic syndrome and related conditions.
Cantoni Therapeutics has 1 recorded funding round in the Tech.eu database (amounts undisclosed). Based in Leiden, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-18 | Other | — |
| angel investor,Brabantse Ontwikkelings Maatschappij (BOM),Libertatis Ergo Holding BV (LEH) |
| View deal → |
